Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 1

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

NCT07764237 · tracked via the Priya Life Science UK tracker
Phase
Phase 1
Started
2026-08-11
Last updated
2026-08-19

Condition(s) studied

Respiratory Syncytial Virus (RSV)Human Metapneuomovirus (hMPV)

Investigational drug(s) / intervention(s)

mRNA-1365 (Profile 2) →mRNA-1345 (Profile 1) →mRNA-1345 (Profile 3) →

mRNA-1365 (Profile 2): Sterile liquid for injection

mRNA-1345 (Profile 1): Sterile liquid for injection

mRNA-1345 (Profile 3): Sterile liquid for injection

Study summary

The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
Accepted
Key Inclusion Criteria: * In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history and physical examination. * Body mass index within the range 18.5 to 35 kg/m2 (inclusive). Key Exclusion Criteria: * History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic, or any components of an mRNA vaccine or therapeutic. * Abnormal screening clinical laboratory values for total white blood cell count, hemoglobin, hematocrit, alanine aminotransferase, aspartate aminotransferase, creatinine, alkaline phosphatase, or total bilirubin \>Grade 1, or platelets ≥Grade 1. * History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures. * History of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infectious disease. * Participants with immune-mediated (autoimmune) conditions are generally excluded. * Received a licensed RSV vaccine or participated in a study in which vaccines against RSV and/or hMPV were administered to participants alone, or as part of a combination vaccine, at any time in the past. Note: Other inclusion and exclusion criteria may apply.

Primary outcome measure(s)

  • Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) — Up to Day 7 (the day of study intervention and 6 subsequent days)
  • Number of Participants with Unsolicited Adverse Events (AEs) — Up to Day 28 (the day of study intervention and 27 subsequent days)
  • Number of Participants with Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), Any AEs Leading to Study Discontinuation, and AEs of Special Interest (AESIs) — Up to End of Study (EOS) (Day 181)

Trial sites (10)

FacilityCityRegionStatus
Diex Recherche Quebec Québec Quebec Recruiting
Diex Recherche Victoraville Victoriaville Quebec Recruiting
MAC Clinical Research Manchester Greater Manchester Not Yet Recruiting
Southampton General Hospital, NHS Southampton Hampshire Not Yet Recruiting
Norfolk and Norwich University Hospital, NHS Norwich Norfolk Not Yet Recruiting
University Hospital Birmingham, NHS Birmingham West Midlands Not Yet Recruiting
Royal Free Hospital, NHS London United Kingdom Not Yet Recruiting
Guys and St. Thomas Hospital, NHS London United Kingdom Not Yet Recruiting
St. George University Hospital, NHS London United Kingdom Not Yet Recruiting
Royal Victoria Infirmary, NHS Newcastle United Kingdom Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07764237 on ClinicalTrials.gov ↗ ← All trials in the UK